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We performed global RNA transcript analysis and
comprehensive gene group analysis of peripheral
blood leukocyte (PBL) RNA from two groups of
matched sib-pairs that were discordant for either
schizophrenia (n¼33 sib-pairs) or bipolar disor-
der (n¼5 sib-pairs). The pairs chosen for these
analyses were selected from families with known
patterns of genetic linkage (5q for schizophrenia
and 6q for bipolar disorder). At the single gene
level, we obtained lists of the transcripts with the
most significant changes in expression and from
these lists determined those with the highest
degree of predictive power for classifying subjects
according to diagnosis in these samples. At the
gene group level, we comprehensively analyzed
pairwise expression changes of more than 4,000
functional groups and cytogenetic locations, and
present a novel method of displaying these data
that we term ‘‘cytogenomic’’ mapping. Verifica-
tion of selected changes in expression was per-
formed using quantitative real-time RT-PCR.
Our results provide compelling evidence for the
utility of analyzing PBL RNA for changes in
expression in neuropsychiatric disorders.
 2005 Wiley-Liss, Inc.
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INTRODUCTION
We have recently reported strong suggestive genome-
wide linkages for both schizophrenia and bipolar disorder in
pedigrees from the Portuguese IslandCollection [PIC; see Pato
et al., 2004; Sklar et al., 2004]. In a follow-up study of bipolar
disorder using a denser SNP-based genotyping method,
we achieved genome-wide significance for linkage at 6q22
[Middleton et al., 2004]. In schizophrenia, the peak linkage
signalswere obtained on chromosome 5q31-35. In order to help
expedite the selection of candidate genes in these (and other)
regions, we have implemented a strategy involving the
measurement of changes in gene expression in peripheral
blood leukocytes (PBLs) in discordant sib-pairs from the two
pedigree sets.
The analysis of mRNA transcript levels in PBLs from living
subjects offers several advantages compared with studies
involving only end point postmortem tissue specimens. Such
advantages include the ability to completely match subject
characteristics such as age, gender, family background, time
of blood draw, geographical/environmental variables, diet,
and the cellular composition of the samples. Moreover, it also
becomes feasible to design studies that examine expression
profiles of PBLs during the progression of the disease, or in
response to drug treatments. These gene expression patterns,
when obtained in well-controlled studies, have increased the
power to help refine candidate gene selection for mutational
screening, aswell as obtain lists of geneswith predictive power
for classifying different diseases and their treatment response.
Indeed, in the cancer field, it has become standard practice at
some clinics that specialize in childhood leukemias to compare
the expression profiles of PBLs or lymphocytes on all patients.
These expression patterns not only correctly subtype the
leukemia, but also serve as highly accurate predictors of the
disease course [e.g., Yeoh et al., 2002].
In neuropsychiatric diseases, no studies to date have been
published on the potential utility of gene expression profiling
of PBLs for either diagnosis or disease characterization.
There has been, however, at least one study to date examining
the gene expression profile of transformed lymphoblasts from
a small number of subjects with schizophrenia in a single
pedigree, which showed promising results [Vawter et al.,
2004]. In the present, study, we wished to determine the
changes in gene expression in a larger sample involving 33
sib-pairs from families segregating for schizophrenia from the
PIC population where we had detected strong linkage to 5q.
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TABLE I. Largest Significant Pairwise Expression Changes in Schizophrenia Sib Pairs
Probe ID Fold change P-value Gene title Symbol Location
Increased expression
201743_at 2.53 0.00108 CD14 antigen CD14 5q31.1
202437_s_at 2.36 0.00864 Cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 2p21
204614_at 2.33 0.00331 Serine (or cysteine) proteinese inhibitor, clade B
(ovalbumin), member 2
SERPINB2 18q21.3
201109_s_at 2.16 0.00990 Thrombospondin 1 THBS1 15q15
221731_x_at 2.08 0.01777 Chondroitin sulfate proteoglycan 2 (versican) CSPG2 5q14.3
212681_at 2.04 0.02058 Erythrocyte membrane protein band 4.1-like 3 EPB41L3 18p11.32
210111_s_at 2.02 0.00043 KIAA0265 protein KIAA0265 7q32.3
205098_at 1.97 0.00330 Chemokine (C-C motif) receptor 1 CCR1 3p21
217996_at 1.96 0.00407 Pleckstrin homology-like domain, family A, member 1 PHLDA1 12q15
202435_s_at 1.96 0.03702 Cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 2p21
201110_s_at 1.90 0.04771 Thrombospondin 1 THBS1 15q15
20436_s_at 1.90 0.04004 Cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 2p21
218559_s_at 1.86 0.00091 v-maf musculoaponeurotic fibrosarcoma oncogene homolog
B (avian)
MAFB 20q11.2-q13.1
217997_at 1.85 0.01743 Pleckstrin homology-like domain, family A, member 1 PHLDA1 12q15
212636_at 1.82 0.00120 Quaking homolog, KH domain RNA binding (mouse) QKI 6q26-27
211776_s_at 1.80 0.01556 Erythrocyte membrane protein band 4.1-like 3 EPB41L.3 18p11.32
206710_s_at 1.80 0.01838 Erythrocyte membrane protein band 4.1-like 3 EPB41L.3 18p11.32
204470_at 1.77 0.02088 Chemokine (C-X-C motif) ligand 2 CXCL2 4q21
212993_at 1.77 0.01313 Sin3-associated polypetide, 18 kDa – 9q34.3
218195_at 1.76 0.00527 Chromosome 6 open reading frame 211 C6orf211 6q25.1
208892_a_at 1.75 0.01232 Dual specificity phosphatase 6 DUSP6 12q22-q23
204620_s_at 1.75 0.03852 Chondroitin sulfate proteoglycan 2 (versican) CSPG2 5q14.3
201694_s_at 1.74 0.01116 Early growth response 1 EGR1 5q31.1
213836_s_at 1.74 0.00421 Hypothetical protein FLJ10055 FLJ10055 17q24.3
206343_s_at 1.73 0.01010 Neuregulin 1 NRG1 8p21-p12
204049_s_at 1.72 0.02217 Phosphatase and actin regulator 2 PHACTR2 6q24.1
204619_s_at 1.69 0.03953 Chondroitin sulfate proteoglycan 2 (versican) CSPG2 5q14.3
201108_s_at 1.69 0.02084 Thrombospondin 1 THBS1 15q15
203973_s_at 1.67 0.00375 CCAAT/enhancer binding protein (C/EBP), delta CEBPD 8p11.2-p11.1
205863_at 1.67 0.03650 S100 calcium binding protein A12 (calgranulin C) S100A12 1q21
207719_x_at 1.66 0.02342 KARP-1 binding protein KAB 1q44
222243_s_at 1.65 0.00014 Transducer of ERBB2, 2 TOB2 22q13.2-q13.31
205922_at 1.65 0.00371 Vanin 2 VNN2 6q23-q24
222028_at 1.65 0.00093 Zinc finger protein 45 (a Kruppel-associated box (KRAB)
domain polypeptide)
ZNF45 19q13.2
220088_at 1.64 0.03512 Complement component 5 receptor 1 (C5a ligand) C5R1 19p13.3-q13.4
205495_s_at 1.63 0.01893 Granulysin GNLY 2p12-q11
210844_x_at 1.63 0.00142 Catenin (cadherin-associated protein), alpha 1, 102 kDa CTNNA1 5q31
208891_at 1.63 0.01859 Dual specificity phosphatase 6 DUSP6 12q22-q23
208716_s_at 1.63 0.00689 Putative membrane protein LOC54499 1q22-q25
200765_x_at 1.62 0.00056 Catenin (cadherin-associated protein), alpha 1, 102 kDa CTNNA1 5q31
Decreased expression
209170_s_at 1.89 0.01378 Glycoprotein M6B GPM6B Xp22.2
213797_at 1.65 0.02433 Viperin cig5 2p25.2
212621_at 1.63 0.01017 KIAA0286 protein KIAA0286 12q13.2
214059_at 1.61 0.03891 Interferon-induced protein 44 IFI44 1p31.1
219863_at 1.61 0.01801 Cyclin-E binding protein 1 CEB1 4q22.1-q23
210797_s_at 1.60 0.00820 20-50-oligoadenylate synthetase-like OASL 12q24.2
214453_s_at 1.55 0.04213 Interferon-induced protein 44 IFI44 1p31.1
216252_x_at 1.50 0.02649 Tumor necrosis factor receptor superfamily, member 6 TNFRSF6 10q24.1
205660_at 1.47 0.00608 20-50-oligoadenylate synthetase-like OASL 12q24.2
210676_x_at 1.45 0.01189 RAN binding protein 2-like 1 RANBP2L1 2q13
204780_s_at 1.44 0.00725 Tumor necrosis factor receptor superfamily, member 6 TNFRSF6 10q24.1
210425_x_at 1.44 0.03848 Golgin-67 GOLGIN-67 15q11.2
204747_at 1.42 0.02484 Interferon-induced protein with tetratricopeptide repeats 4 IFIT4 10q24
215831_at 1.42 0.02860 PRO1621 protein PRO1621 11
203992_s_at 1.41 0.00763 Ubiquitously transcribed tetratricopeptide repeat,
X chromosome
UTX Xp11.2
220104_at 1.41 0.01244 Zinc finger CCCH type, antiviral 1 ZC3HAV1 7q34
213703_at 1.36 0.00483 Hypothetical protein LOC150759 LOC150759 2q11.2
204083_s_at 1.35 0.02416 Tropomyosin 2 (beta) TPM2 9p13.2-p13.1
204369_at 1.34 0.04573 Phosphoinositide-3-kinase, catalytic, alpha polypeptide PIK3CA 3q26.3
216358_at 1.33 0.01088 SWI/SNF related, matrix associated actin dependent
regulator of chromatin, subfamily e1
SMARCE1 17q21.2
217506_at 1.30 0.00600 Transcribed sequence with moderate similarity to
hypothetical protein FLJ20378
— —
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In addition, we performed a highly focused analysis of gene
expression alterations in five sib-pairs from specific PIC
families segregating for bipolar disorder that had linkage
to 6q22. Our aims were to determine if this approach would
have diagnostic utility and also help identify candidate
genes with abnormal expression patterns in the regions that
display significant linkage. Importantly, we have not assumed
a priori that the changes in transcript levels that occur in
PBLs necessarily indicate that similar patterns of expression
alterations will be evident in the brains of subjects with
schizophrenia or bipolar disorder. Rather, wemerely hypothe-
sized that if underlying genetic abnormalities altered tran-
script expression in a consistent manner, we would be able to
detect such effects if the transcript was expressed in PBLs.
We suggest that such changes, when present, may reflect
primary pathogeneticmechanisms, or simply conserved patho-
physiological features of the illness or its treatment.
METHODS
Subject Ascertainment
Methods for subject ascertainment and classification are
the same as previously described [Pato et al., 2004]. Families
with two or more affected individuals were ascertained from
systematic screening of all treating clinicians, treatment
facilities, social services, and extensive family interviews.
In theAzores, all four psychiatric hospitals and the two general
hospitals participated in the study. Similarly in Madeira, both
psychiatric hospitals and the general hospital participated.
On the mainland, families were identified by our collaborators
at the University of Coimbra. Informed consent was obtained
in writing from all subjects for participation in the genetic and
family studies. Collection of blood and family history informa-
tion was approved by all of the appropriate Institutional
Review Boards. Best estimate diagnoses according to DSM-IV
were made by two independent blinded researchers. All cases,
where therewasdisagreement,were reviewedbya third senior
psychiatrist blind to the status of the case (MT Pato, MD).
The specific subjects for this study were selected as gender-
and age-matched discordant sibs from families that partici-
pated in our linkage studies. For studies of schizophrenia,
40 such sib-pairs were selected from all families segregating
for schizophrenia from the PIC population where we had
detected strong linkage to 5q andhad cell samples available for
RNA purification. For bipolar disorder, we performed a highly
focused analysis of gene expression alterations in five sib-pairs
from specific PIC families segregating for bipolar disorderwith
linkage to 6q22. These 45 age- and gender-matched sib-pairs
were screened for alterations in white blood cell composition
(see below), which eliminated five schizophrenia sib-pairs from
further consideration. After processing all arrays, a priori
quality control criteria (excessive 30/50 ratios for beta actin and
GAPDH,and/or scale factors exceeding10.0 for any subject) led
us to eliminate two additional sib-pairs from our analyses.
Thus, in total, 33 sib-pairs were used for our schizophrenia
studies andfive sib-pairs for our bipolar studies. To achieve the
highest level of subject matching and quality control, we found
it helpful to examine cellular composition using differential
white blood cell counts (Wright’s stain method). All of the
samples included in this report had normal blood count
differentials. The specific age and blood cell composition values
for the schizophrenic group are the same as previously
described (Petryshen et al., 2004; 22 female pairs, 11 male
pairs;meanagesSDofaffectedsandunaffecteds¼ 44.8 12.4
and 42.8 12.9, respectively; mean neutrophil counts¼
58.9 4.8% and 56.8 4.7%; mean lymphocyte counts¼
34.1 7.0% and 33.9 4.2%). For the bipolar subject pairs,
the mean valuesSD for affecteds and unaffecteds was
age¼ 41.2 5.8 and 40.8 11.4; neutrophils¼ 55.4 4.4,
59.2 2.9; lymphocytes¼ 38.4 4.7, 35.2 2.8. There were
no significant pairwise or unpaired differences between the
subject groups and the matched controls for any of these
values.
Microarray Gene Expression Sample Preparation
Total RNA was extracted from leukocyte cell preparations
from 66 siblings selected from the 40 schizophrenia pedigrees
used in a previous linkage study [see Sklar et al., 2004] and
10 siblings selected from the 25 bipolar pedigrees used in a
previous linkage study [see Middleton et al., 2004]. Total
RNA quality and quantity was assessed using UV spectro-
photometry and comparison of 28S:18S ratios with the
Bioanalyzer RNA Nano Chip (Agilent). Microarray samples
were labeled and processed according to standard protocols,
TABLE I. (Continued )
Probe ID Fold change P-value Gene title Symbol Location
208931_s_at 1.30 0.00297 Interleukin enhancer binding factor 3, 90 kDa ILF3 19p13.2
214982_at 1.30 0.00598 U5 snRNP-specific protein, 200-KD U5-200KD 2q11.2
210232_at 1.30 0.02568 Cell division cycle 42 (GTP binding protein, 25 kDa) CDC42 1p36.1
216110_x_at 1.30 0.04868 Homo sapiens cDNA FLJ14080 fis, clone HEMBB1002152 — 2q31.1
222307_at 1.30 0.02200 Hypothetical protein LOC282997 LOC282997 10q25.3
219209_at 1.30 0.01517 Melanoma differentiation associated protein-5 MDA5 2p24.3-q24.3
207115_x_at 1.29 0.02557 mbt domain containing 1 MBTD1 17q21.33
220809_at 1.28 0.03526 Hypothetical protein FLJ14327 FLJ14327 16q23.2
210095_s_at 1.28 0.00346 Insulin-like growth factor binding protein 3 IGFBP3 7q13q-12
221728_x_at 1.28 0.01621 X (inactive)-specific transcript XIST Xq13.2
217104_at 1.28 0.02709 Hypothetical protein LOC283687 LOC283687 15q24.3
211115_x_at 1.28 0.00056 Survival of motor neuron protein interacting protein 1 SIP1 14q13
209321_s_at 1.28 0.00881 Adenylate cyclase 3 ADCY3 2p24-p22
209387_s_at 1.28 0.03185 Transmembrane 4 superfamily member 1 TM4SF1 3q21-q25
209314_s_at 1.28 0.00716 HBS1-like (S. cerevisiae) HBS1L 6q23-q24
214487_s_at 1.27 0.01701 RAP2B, member of RAS oncogene family RAP2B 3q25.2
202861_at 1.27 0.03941 Period homolog 1 (Drosophila) PER1 17p13.1-p12
218706_s_at 1.27 0.01122 HCV NS3-transactivated protein 2 NS3TP2 5q23.3
220704_at 1.27 0.01071 Zinc finger protein, subfamily 1A, 1 (Ikaros) ZNFN1A1 7p13-p11.1
Shading indicates more than one probe set identified a change in this transcript among those listed in this table; these can be considered independent
validations.
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TABLE II. Largest Significant Pairwise Expression Changes in Bipolar Sibling Pairs
Probe ID Fold change P-value Gene title Symbol Location
Increased expression
203556_at 2.08 0.03908 Zinc fingers and homeoboxes 2 ZHX2 8q24.13
209332_s_at 1.94 0.01483 MAX protein MAX 14q23
202351_at 1.88 0.01839 Integrin, alpha V (vitronectin receptor, alpha
polypeptide, antigen CD51)
ITGAV 2q31-q32
201648_at 1.87 0.01542 Janus kinase 1 (a protein tyrosine kinase) JAK1 1p32.3-p31.3
211994_at 1.78 0.02617 Protein kinase, lysine deficient 1 PRKWNK1 12p13.3
208638_at 1.76 0.00846 Thioredoxin domain containing 7
(protein disulfide isomerase)
TXNDC7 2p25.1
208856_x_at 1.76 0.03823 Ribosomal protein, large, PO RPLP0 12q24.2
214737_x_at 1.74 0.02115 Heterogeneous nuclear ribonucleoprotein C (C1/C2) HNRPC 14q11.2
212626_x_at 1.67 0.03681 Heterogeneous nuclear ribonucleoprotein C (C1/C2) HNRPC 14q11.2
221491_x_at 1.64 0.01463 Major histocompatibility complex, class II, DR beta 3 HLA-DRB3 6p21.3
209835_x_at 1.64 0.04319 CD44 antigen (homing function and Indian blood
group system)
CD44 11p13
200745_s_at 1.61 0.00057 Guanine nucleotide binding protein (G protein),
beta polypeptide 1
GNB1 1p36.33
207616_s_at 1.60 0.03284 TRAF family member-associated NFKB activator TANK 2q24-q31
209331 _s_at 1.59 0.00476 MAX protein MAX 14q23
200746_s_at 1.56 0.00108 Guanine nucleotide binding protein (G protein), beta
polypepide 1
GNB1 1p36.33
209586_s_at 1.55 0.02552 TcD37 homolog HTCD37 1q21
222294_s_at 1.54 0.03711 RAB27A, member RAS oncogene family RAB27A 15q15-q21.1
200084_at 1.50 0.03447 Small acidic protein SMAP 11p15.2
204396_s_at 1.50 0.00192 G protein-coupled receptor kinase 5 GRK5 10q24-qter
204373_s_at 1.48 0.01338 Centrosome-associated protein 350 CAP350 1p36.13-q41
201061_s_at 1.48 0.03523 Stomatin STOM 9q34.1
218284_at 1.48 0.04873 DKFZP586N0721 protein DKFZP586N0721 15q22.31
202698_x_at 1.46 0.04149 Cytochrome-c oxidase subunit IV isoform 1 COX4I1 16q22-qter
201560_at 1.44 0.04648 Chloride intracellular channel 4 CLIC4 1p36.11
206544_x_at 1.43 0.03723 SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily a2
SMARCA2 9p22.3
202061_s_at 1.42 0.00889 sel-1 suppressor of lin-12-like (C. elegans) SEL1L 14q24.3-q31
202840_at 1.41 0.01641 TAF15 RNA polymerase II, TATA box binding protein
(TBP)-associated factor, 68 kDa
TAF15 17q11.1-q11.2
204735_at 1.40 0.00917 Phosphodiesterase 4A, cAMP-specific
(phosphodiesterase E2 dunce homolog, Drosophila)
PDE4A 19p13.2
204070_at 1.39 0.01290 Retinoic acid receptor responder (tazarotene induced) 3 RARRES3 11q23
208938_at 1.39 0.00493 Papillary renal cell carcinoma (translocation-associated)PRCC 1q21.1
201144_s_at 1.38 0.02715 Eukaryotic translation intiation factor 2, subunit 1
alpha, 35 kDa
EIF2S1 14q24.1
205049_s_at 1.38 0.03527 CD79A antigen (immunoglobulin-associated alpha) CD79A 19q13.2
200605_s_at 1.37 0.01436 Protein kinase, cAMP-dependent regulatory, type 1,
alpha (tissue specific extinguisher 1)
PRKAR1A 17q23-q24
200885_at 1.36 0.04139 Ras homolog gene family, member C RHOC 1p13.1
204489_s_at 1.33 0.01981 CD44 antigen (homing function and Indian blood
group system)
CD44 11p13
214271_x_at 1.33 0.02639 Ribosomal protein L12 RPL12 9q34
212014_x_at 1.33 0.02870 CD44 antigen (homing function and Indian blood
group system)
CD44 11p13
212352_s_at 1.31 0.04363 Transmembrane trafficking protein TMP21 14q24.3
214836_x_at 1.31 0.04004 Kappa-immunoglobulin germline pseudogene
(Chr22.4) variable region (subgroup V kappa II)
— 2p11.2
221737_at 1.31 0.03167 Guanine nucleotide binding protein
(G protein) alpha 12
GNA12 7p22-p21
Decreased expression
214022_s_at 1.68 0.01385 Interferon induced transmembrane protein 1 (9–27) IFITM1 11p15.5
201662_s_at 1.64 0.03130 Acyl-CoA synthetase long-chain family member 3 ACSL3 2q34-q35
208800_at 1.60 0.04517 Signal recognition particle 72 kDa SRP72 4q11
201523_x_at 1.54 0.01262 Ubiquitin-conjugating enzyme E2N (UBC13 homolog
yeast)
UBE2N 12q22
205099_s_at 1.47 0.02248 Chemokine (C-C motif) receptor 1 CCR1 3p21
219557_s_al 1.45 0.03653 Nuclear receptor interacting protein 3 NRIP3 11p15.3
218852_at 1.44 0.04879 Chromosome 14 open reading frame 10 C14orf10 14q13.2
201524_x_at 1.42 0.03537 Ubiquitin-conjugating enzyme E2N (UBC13 homolog,
yeast)
UBE2N 12q22
206689_s_at 1.41 0.04480 Transcription factor binding to IGHM enhancer 3 TFE3 Xp11.22
(Continued)
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hybridized to the Human Genome U133A GeneChip (Affy-
metrix), washed and stained on a fluidics station (Affymetrix)
according to the EukGE-WS2 protocol, and scanned using the
G2500A Gene Array Scanner. The scan files were normalized
using the Gene Chip Robust Multichip Analysis method
[Irizarry et al., 2003].
Statistical changes in gene expression were determined in
pairwise fashion using the Significance Analysis algorithm
(GeneTraffic, Iobion). All of the transcript probes that were
significantly changed (P< 0.05)were ranked bymean pairwise
fold change. This was applied to both the entire genome for
schizophrenia and bipolar disorder (Tables I and II, respec-
tively) and each of the candidate genome regions (5q and 6q)
(Table III). Notably, because of the relatively small number of
sib-pairs used in the bipolar study, we present the top fold
changes in the 6q locus using a threshold of P< 0.10 for this
disorder.
Prediction Classification
From the lists of significantly changed genes, we also sought
to derive a preliminary list of genes whose expression patterns
might be useful as predictors of diagnosis. For this analysis, we
used the Class Predictor algorithm (GeneSpring) to predict the
value, or ‘‘class,’’ of individual parameters in the set of samples.
This was done using both the Euclidian nearest neighbor
method and support vector machine (SVM)method. The genes
with the highest predictive power in our dataset were ranked
by their predictive strength (Table IV). Importantly, we point
out that because we used the methods that require defining a
training set, the list we present still requires validation in an
independent cohort.
Gene Group Analysis
We determined the relevant biological pathway information
in our expression data using custom-written software [Path-
Stat; see Middleton et al., 2004] to extract distributions of
differential expression ratios for functionally related groups
of transcripts using publicly curated databases. These data-
bases included the different groups of the Gene Ontology
database (http://us.expasy.org/cgi-bin/enzyme-search-cl), the
Kyoto Encyclopedia of Genes and Genomes database (http://
www.genome.ad.jp/kegg/pathway.html), the Enzyme Commis-
sion database (http://us.expasy.org/cgi-bin/enzyme-search-cl),
and the Protein Family (pFam) database (http://www.sanger.
ac.uk/Software/Pfam/search.shtml). Lists of the specific pro-
bes on the Affymetrix U133A GeneChip that belong to each of
these groupings are available in a single annotated file from
the Affymetrix NetAffx website (http://www.affymetrix.com/
support/technical/byproduct.affx?product¼hgu133-20). To per-
form the pathway analyses, the scaled and normalized gene
expression level was first calculated using robust multi-chip
analysis (RMA), and then the expression level of each gene in
the affected pairs (BP or SCZ subjects) was compared to the
corresponding expression level of the samegene in thematched
TABLE II. (Continued )
Probe ID Fold change P-value Gene title Symbol Location
205382_s_at 1.38 0.03956 D component of complement (adipsin) DF 19p13.3
212414_s_at 1.37 0.03062 Septin 6 SEPT6 Xq25
218543_s_at 1.35 0.04712 Zinc finger CCCH type domain containing 1 ZC3HDC1 7q34
212658_at 1.34 0.04834 Lipoma HMGIC fusion partner-like 2 LHFPL2 5q14.1
215424_s_at 1.33 0.00794 SKI interacting protein SKIIP 14q24.3
217960_s_at 1.33 0.03531 Translocase of outer mitochondrial membrane 22
homolog (yeast)
TOMM22 22q12-q13
203077_s_at 1.28 0.04364 SMAD, mothers against DPP homolog 2 (Drosophila) SMAD2 18q21.1
202164_s_at 1.28 0.03718 CCR4-NOT transcription complex, subunit 8 CNOT8 5q31-q33
218753_at 1.28 0.03344 Hypothetical protein FLJ10307 FLJ10307 1p35.2
203055_s_at 1.28 0.02857 Rho guanine nucleotide exchange factor (GEF) 1 ARHGEF1 19q13.13
212397_at 1.28 0.02452 Radixin RDX 11q23
221490_at 1.28 0.04365 Ubiquitin associated protein 1 UBAP1 9p22-p21
212766_s_at 1.26 0.04957 Hypothetical protein FL12671 FLJ12671 1q23.1
201083_s_at 1.26 0.02615 BCL2-associated trancription factor BCLAF1 6q22-q23
209704_at 1.25 0.04701 Likely ortholog of mouse metal response
element binding transcription factor 2
M96 1p22.1
218214_at 1.25 0.04535 Hypothetical protein FLJ11773 FLJ11773 12q13.13
201978_s_at 1.25 0.04803 KIAA0141 gene product KIAA0141 5q31.3
208811_s_at 1.24 0.02519 DnaJ (Hsp40) homolog, subfamily B, member 6 DNAJB6 7q36.3
218403_at 1.24 0.03064 Hypothetical protein HSPC132 HSPC132 12q24.31
201856_s_at 1.21 0.03464 Zinc finger RNA binding protein ZFR 5p13.3
201712_s_at 1.21 0.03245 RAN binding protein 2 RANBP2 2q12.3
220349_s_at 1.21 0.01209 Endo-beta-N-acetylglucosaminidase FLJ21865 17q25.3
217956_s_at 1.20 0.00290 E-1 enzyme MASA 4q21.3
217208_s_at 1.19 0.04560 Discs, large homolog 1 (Drosophila) DLG1 3q29
202947_s_at 1.19 0.02718 Glycophorin C (Gerbich blood group) GYPC 2q14-q21
204777_s_at 1.18 0.00702 Mal, T-cell differentiation protein MAL 2cen-q13
212757_s_at 1.17 0.04972 Calcium/calmodulin-dependent protein kinase
(CaM kinase) II gamma
CAMK2G 10q22
213560_at 1.17 0.04758 Growth arrest and DNA-damage-inducible, beta GADD45B 19p13.3
218615_s_at 1.16 0.00929 Hypothetical protein FLJ10902 FLJ10902 3q13.33
201966_at 1.15 0.04461 NADH dehydrogenase (ubiquinone) Fe-S protein 2,
49 kDa (NADH-coenzyme Q reductase)
NDUFS2 1q23
216333_x_at 1.15 0.02708 Tenascin XB TNXB 6p21.3
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control subject. This ratio was generated only if the expression
level in at least one of the sampleswas greater than themedian
RMA normalized signal intensity of the dataset (computed
signal 12 or higher). PathStat then compiled the gene-by-
gene expression ratios for each functional group, as well as all
the genes on the chip, and calculated a t statistic for the group
that was proportional to the number of standard deviations
that group’s expression had shifted in the affected subject pair,
adjusted for the number of transcripts in each group. Gene
group ratios were only generated if an average of at least three
transcript ratios were computed in each group [Middleton
et al., 2002, 2004]. For each disease, we present the omnibus
data (all 5 or 33 subject pairs combined) for this report. This
highly conservative method enables one to detect large-scale
coordinated changes in functional gene group expression in
complex treatment paradigms or disease states. In the present
analysis, PathStat mapped our expression data to a total of
more than 3,000 separate publicly curated pathways. Tables of
the top 25 increased and decreased gene group alterations in
each disorder were generated.
Cytogenomics
In addition to the functional gene groups, we also utilized a
new approach for mining and mapping expression changes
within the context of cytogenetic loci, an approach we term
‘‘cytogenomics.’’ For example, single megabase bins generally
contain approximately 8–12 gene probes of which approxi-
mately half will be expressed in the blood or brain of human
subjects. Each of these megabase bins was treated as a gene
group cluster and the pairwise and genewise differences in
expression used to create high-density cytogenomic Z score
plots (Fig. 1). These Z score plots were compared directly with
the NPL Z score plot and a Chi Square plot derived from the
linkage and association analyses of schizophrenia and bipolar
disorder. Two examples of the utility of this approach are
provided (Fig. 2). To perform the genome-wide association
analysis, we used Varia (Silicon Genetics) to construct a
haplotype map (E-M algorithm) of the complete set of 25
bipolar families genotyped with the Affymetrix Human
Mapping Assay Xba 141 [see Middleton et al., 2004]. A
preliminary genome-wide family-based Transmission Dise-
quilibrium Test (TDT) was performed and themost significant
results for the entire genome were listed (Table VIII). More-
over, the Chi Square values from this analysis were overlaid
with the expression and linkage plots for chromosome 6q
(Fig. 2).
Microarray Validation With Quantitative
Real-Time RT-PCR (qRT-PCR)
Validation of selected changes in expression was per-
formed using quantitative real-time RT-PCR (qRT-PCR),
using RNA from 19 of the 33 schizophrenia sibpairs and all
5 bipolar sibpairs for whom sufficient RNA was available.
Primer sequences for each gene of interestwere designedusing
Primer3 software, and are available upon request. For the RT
reactions, equal amounts of total RNA (250 ng) from each
sample were reverse transcribed (Superscript II protocol) with
an oligo dT primer prior to quantitative PCR according to the
TABLE III. Changed Individual Probesets in Loci of Interest
Probe ID
Fold
change P-value Gene title Symbol Location
Schizophrenia 5q linkage region (P<0.05)
201743_at 2.53 0.00108 CD14 antigen CD14 5q31.1
201694_s_at 1.74 0.01116 Early growth response 1 EGR1 5q31.1
210844_x_at 1.63 0.00142 Catenin (cadherin-associated protein), alpha 1, 102 kDa CTNNA 1 5q31
200765_x_at 1.62 0.00056 Catenin (cadherin-associated protein), alpha 1, 102 kDa CTNNA 1 5q31
203218_at 1.59 0.00311 Mitogen-activated protein kinase 9 MAPK9 5q35
217840_at 1.48 0.01072 DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 DDX41 5q35.3
214658_at 1.46 0.03732 CGI-109 protein CGI-109 5q23.1
201506_at 1.46 0.02373 Transforming growth factor, beta-induced, 68 kDa TGFBI 5q31
205896_at 1.44 0.00904 Solute carrier family 22 (organic cation transporter), member 4 SLC22A4 5q31.1
202360_at 1.36 0.00170 Mastermind-like 1 (Drosophila) MAML1 5q35
202227_s_at 1.36 0.00387 Bromodomain containing 8 BRD8 5q31
220495_s_at 1.34 0.01182 Chromosome 5 open reading frame 14 C5orf14 5q31.2
212900_at 1.33 0.03403 SEC24 related gene family, member A (S. cerevisiae) SEC24A 5q31.2
212137_at 1.31 0.01715 Likely ortholog of mouse Ia related protein LARP 5q33.2
Bipolar 6q linkage region (P< 0.10)
208623_s_at 2.57 0.08125 Villin 2 (ezrin) VIL2 6q25.2-q26
210105_s_at 2.01 0.08039 FYN oncogene related to SRC, FGR, YES FYN 6q21
216033_s_at 1.66 0.09324 FYN oncogene related to SRC, FGR, YES FYN 6q21
212265_at 1.41 0.09018 Quaking homolog, KH domain RNA binding (mouse) QKI 6q26-27
201915_at 1.17 0.02738 SEC63-like (S. cerevisiae) SEC63 6q21
221311_x_at 1.17 0.09196 Hypothetical protein dJ122O8.2 DJ12208.2 6q14.2-q16.1
210156_s_at 1.16 0.02719 Protein-L-isoaspartate (D-aspartate) O-methyltransferase PCMT1 6q24-q25
204207_s_at 1.14 0.07257 RNA guanylyltransferase and 50-phosphatase RNGTT 6q16
205116_at 1.11 0.05556 Laminin, alpha 2 (merosin, congenital muscular dystrophy) LAMA2 6q22-q23
215904_at 1.09 0.06463 Myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila)
MLLT4 6q27
206005_s_at 1.08 0.07908 Chromosome 6 open reading frame 84 C6orf84 6q15
217399_s_at 1.03 0.03835 Forkhead box O3A FOXO3A 6q21
209608_s_at 1.19 0.09159 Acetyl-coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme
A thiolase)
ACAT2 6q25.3-q26
201083_s_at 1.26 0.02615 BCL2-associated transcription factor 1 BCLAF1 6q22-q23
PBL RNA in Schizophrenia and Bipolar Disorder 17
standard TaqMan protocol (Applied Biosystems) using SYBR-
Green Idye for amplicondetectionwith anABI-7000RealTime
Sequence Detection System (Applied Biosystems). Statistical
analysis was performed using a pairwise repeated measures
ANOVA comparing the difference in the number of cycles to
threshold (DCt) between each target gene and alpha tubulin.
Group differences were calculated by determining the mean
pairwise difference in thedeltaCt values per subject group (the
DDCt), and a fold change calculated according to the formula,
Fold change¼ 2DDCt.
RESULTS
Sib-Pair Analyses
Global significance analysis. Of the 22,283 probe sets
on the array, in a strict pairwise analysis with the RMA
normalized data, more than 2,000 genes showed significant
changes in expression in our schizophrenia sib-pairs and
248 genes showed significant changes in expression in our
much smaller set of bipolar sib-pair data (P< 0.05). Given the
larger number of samples used in the schizophrenia analysis,
TABLE IV. Genes With Most Power for Distinguishing Affected and Control Subjects
Probe ID
Pred
strength Map Product LOI
201253_s_at 34.51 16q13 CDP-diacylglycerol–inositol 3-phosphatidyltransferase
(phosphatidylinositol synthase)
207850_at 34.51 4q21 Chemokine (C-X-C motif) ligand 3
205098_at 33.18 3p21 Chemokine (C-C motif) receptor 1
204524_at 30.9 16p13.3 3-Phosphoinositide dependent protein kinase-1
221732_at 30.9 17q25.3 Ectonucleoside triphosphate diphosphohydrolase 8
203333_at 30.9 1q22 Kinesin-associated protein 3
50374_at 30.9 17q25.3 Hypothetical protein LOC339229
202682_s_at 30.9 3p21.3 Ubiquitin specific protease 4 (proto-oncogene)
221203_s_at 30.9 3q27.3 Hypothetical protein FLJ10201
220046_s_at 30.9 3q26.1 Cyclin L1
213708_s_at 29.97 17q21.1 Transcription factor-like 4
200765_x_at 29.97 5q31.2 Catenin (cadherin-associated protein), alpha 1, 102 kDa  
200919_at 29.36 1p34.3 Polyhomeotic-like 2 (Drosophila)
221983_at 29.36 2q36.2 Chromosome 2 open reading frame 17
212265_at 29.25 6q26-q27 Quaking homolog, KH domain RNA binding (mouse)  
221355_at 29.25 2q33-q34 Cholinergic receptor, nicotinic, gamma polypeptide
200745_s_at 29.25 1p36.33 Guanine nucleotide binding protein (G protein), beta polypeptide 1
204446_s_at 29.25 10q11.2 Arachidonate 5-lipoxygenase
222028_at 29.25 19q13.2 Zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide)
222103_at 29.25 12q13.2 Activating transcription factor 1
208715_at 29.25 1q22-q25 Putative membrane protein
218652_s_at 29.25 4p16.3 Hypothetical protein FLJ20265
205424_at 28.06 17q21.2 ProSAPiP2 protein
208732_at 28.06 8q11.23 RAB2, member RAS oncogene family
204208_at 28.06 6q16 RNA guanylyltransferase and 50-phosphatase  
204336_s_at 28.06 20q13.3 Regulator of G-protein signaling 19
211572_s_at 28.06 20p13 Solute carrier family 23 (nucleobase transporters), member 2
216042_at 28.06 1p36.2 Tumor necrosis factor receptor superfamily, member 25
201632_at 28.06 12q24.31 Eukaryotic translation initiation factor 2B, subunit 1 alpha, 26 kDa
211574_s_at 28.06 1q32 Membrane cofactor protein (CD46, trophoblast-lymphocyte
cross-reactive antigen)
212626_x_at 27.61 14q11.1 Heterogeneous nuclear ribonucleoprotein C (C1/C2)
207943_x_at 27.61 6q24-q25 Pleiomorphic adenoma gene-like 1  
218195_at 27.61 6q25.1 Chromosome 6 open reading frame 211  
221204_s_at 11.9 10q22 Cartilage acidic protein 1
208289_s_at 11.2 11q24 Etoposide induced 2.4 mRNA
210574_s_at 10.06 1p35-p34 Nuclear distribution gene C homolog (A. nidulans)
217414_x_at 9.77 16p13.3 Hemoglobin, alpha 2
206649_s_at 9.572 Xp11.22 Transcription factor binding to IGHM enhancer 3
201083_s_at 9.572 5q23.3 BCL2-associated transcription factor 1  
202711_at 9.572 Xq12 Ephrin-B1
222048_at 9.572 22q11.23 Adrenergic, beta, receptor kinase 2
218753_at 9.572 1p35.3 Hypothetical protein FLJ10307
209331_s_at 9.572 14q23 MAX protein
209889_at 9.13 10q24.2 SEC31-like 2 (S. cerevisiae)
204482_at 9.13 22q11.21 Claudin 5 (transmembrane protein deleted in velocardiofacial syndrome)
214487_s_at 9.13 3q25.2 RAP2B, member of RAS oncogene family
201382_at 9.13 1q24-q25 Siah-interacting protein
209902_at 9.13 3q22-q24 Ataxia telangiectasia and Rad3 related
217826_s_at 9.13 6q16.1 Ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast)  
204070_at 9.13 11q23 Retinoic acid receptor responder (tazarotene induced) 3
LOI, locus of interest based on this population for schizophrenia or bipolar disorder.
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implementing a multiple testing correction (Benjamini-
Hochberg) still produced a list of approximately 300 genes
with significant changes in expression. However, because
such a correction in P-values was not possible with the much
smaller bipolardataset,we chose topresentpurelyuncorrected
P-values in this report.
The40geneswith themost robust increases anddecreases in
expression among those that were significantly affected are
shown for each disorder (Tables I and II). While the limited
sample size does not allow us to make specific comments on
each of the genes in these tables, we have decided to present
these data in order for other groups that may be working on
similar efforts to be able to compare (and potentially combine)
their findings with ours. We do point out that several of the
genes with the most significant changes in expression did not
exhibit large enough alterations to be included in these tables,
which are based purely on fold changes.
Targeted significance analysis. We identified 729
transcript probes on the U133A GeneChip that were localized
to 5q for use in analyzing our SCZ sib-pairs and 431 transcripts
on 6q that were used to analyze expression in our BP sib-pairs.
The 14 genes showing the largest fold changes (increases or
decreases) at each locus were shown using a P-value threshold
of 0.05 for schizophrenia and 0.10 for bipolar disorder
(Table III).
Prediction classification. We used the Class Predictor
Algorithm to identify those genes with the greatest potential
diagnostic utility in schizophrenia and bipolar disorder in this
population. After optimization, thenearest neighbor algorithm
produced a list of 35 transcripts with approximately 95%
accuracy. Overall, 70 of 76 subjects were correctly classified as
a control, BP or SCZ subject based on sib-pair expression
differences, with four subjects misclassified and two subjects
not classified. The SVM method obtained 100% accuracy with
as few as 10 genes. The list of transcripts in both of these
respective classifier lists was nearly identical. For simplicity,
we present the top 50 predictor genes, ranked by their
predictive strength according to the SVMalgorithm (Table IV).
Gene group analysis. We assessed the expression pat-
terns of all publicly curated functional pathways that could be
mapped to theU133AGeneChip content. This analysis ofmore
than 3,000 unique transcript collections revealed a set of gene
groups with robust changes in expression in each disorder
(Table V). Extending this analysis to include groups of genes
located at the same physical position (in 1-MB bins), indicated
fairly strong expression changes in a number of key loci in each
disorder (Table VI). Importantly, we note that the Z scores for
the top affected loci in each disorder were not correlated in the
BP and SCZ datasets.
Cytogenomic mapping of expression abnormalities.
The binning of the data used in the Gene Group Analysis
allowed us to create Z score maps of the pairwise expression
changes in our datasets, which we plotted for comparative
purposes in amanner similar to awhole genome screen (Fig. 1).
We point out that this figure revealed considerably different
cytogenomic profiles for these two disorders. For illustrative
purposes, we have also chosen to display the potential overlap
of genetic and functional genomic signals on chromosomes 5q
for schizophrenia and 6q for bipolar disorder (Fig. 2). This side
by side analysis revealed a fair amount of overlap in the genetic
linkage, association, and functional genomic results as was
suggested by the data (Table VI).
Family-based association. Analysis of haplotype-based
TDT performed by Varia using the 25 bipolar family dataset
revealed a number of genomic regions with nominally signif-
icant linkage disequilibrium (Table VII). Despite the limits of
the resolution of the SNP map used to generate haplotypes
(210 KB), it is notable that several of the haplotype blocks
highlightedare located inproximity toboth the6q linkagepeak
and the gene expression Z score peaks. We have begun to use
higher density SNP genotyping arrays to achieve greater
resolution and explore these intriguing findings inmore detail.
Validation of selected genes with real-time quantita-
tive RT-PCR. In our PBL sib-pairs, we examined the
expression of multiple individual transcripts with an indepen-
dent technique to confirm the accuracy and reliability of the
microarray data. Due to limited RNA, only 19 of the original 33
schizophrenic sib-pairs (but all 5 bipolar sib-pairs) were used
in these studies. Several genes with increased and decreased
expression, including the Sensory and Motor Neuron Derived
Factor (SMDF) variant of Neuregulin 1 (NRG1), Transcription
factor-like 4 (TCFL4), Serotonin Receptor Type 4 (5HT4), and
A Disintegrin and Matrix Metalloproteinase 19 (ADAM19)
were all confirmed as showing the same (or greater) amount of
Fig. 1. Cytogenomic plot of expression abnormalities byMB. To generate thismap, the pairwise differential expression ratio distribution of all expressed
transcripts within 1 MB proximity was determined, and the relative shift in this ratio distribution that compared the entire genome was calculated (as a Z
score). For simplification, only the absolute value of the Z score is shown for each disorder.We note that SCZ and BP data do not display much similarity in
their cytogenomic patterns.
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change seen in the array data (Table VIII). A fifth transcript
(Synaptobrevin 2, or VAMP2) was confirmed as showing the
same direction of change as the array data, but the P-value did
not attain significance (Table VIII).Moreover, other genes that
did not change in the array datawere also confirmed, including
at least two housekeeping genes—alpha tubulin and RNA
Polymerase II (Table VIII). Overall, the mean pairwise fold
changes for these seven transcripts were highly correlated in
the array and PCR datasets (R¼ 0.951).
Genes involved in presynaptic function in the brain
are also altered in PBLs. Expression profiling of post-
mortem brain tissue in subjects with schizophrenia has
revealed some commonly affected intracellular cascades,
particularly those involving presynaptic secretory function
[PSYN genes; see Mirnics et al., 2000]. In order to begin to
address whether PBLs also share some of the same expression
changes as postmortem brain, we searched for significant
(P< 0.05) pairwise expression changes in the PSYN genes in
our schizophrenia data. Interestingly, some 35 unique tran-
scripts were found with such changes. Most of these involved
small differences (less than 20% mean pairwise changes).
However, among the transcripts with 20% or greater increases
in expression were synaptophysin-like protein (SYPL, þ1.4-
fold), synaptosomal-associated protein, 23 kDa (SNAP23,
þ1.4-fold), N-ethylmaleimide-sensitive factor (NSF, þ1.4-
fold), dynactin 3 (DCTN3, þ1.4-fold), sorting nexin 2 (SNX2,
Fig. 2. Regions of putative genetic and functional genomic convergence.
Top, Nonparametric linkage results in families used in amediumresolution
microsatellite scan of chromosome 5q [Sklar et al., 2004]. Data have been
replotted in physical (MB) coordinates (dashed line). The pairwise gene
expression data from 33 discordant sib-pairs from these families were used
to generate an expression Z score plot through the same region (solid line).
Bottom, Families with 6q22 linkage from the 25 used in a previous genome-
wide screen [dashed line; Middleton et al., 2004] were analyzed with a high-
density SNPgenotyping array. Thedata from this samedatasetwereused to
create a whole genome haplotype map and test for TDT. The Chi Square
values obtained in the TDT analysis for chromosome 6q are illustrated
(dotted line). Five age- and gender-matched discordant sib-pairs from these
families were used for leukocyte expression analysis in the current study
(expressionZscoreas solid line).Wenote that thepeakexpressionZscores in
both schizophrenia and bipolar disorder are located near peak linkage
regions, although the positions of the TDT peaks show even more similarity
with the expression Z score peaks.
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þ1.3-fold), vacuolar protein sorting 33B (VPS33B, þ1.3-fold),
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase acti-
vation protein, beta (YWHAB, þ1.2-fold), and vesicle-asso-
ciated membrane protein 4 (VAMP4, þ1.2-fold). On the other
hand, far fewer PSYN transcripts showed pairwise decreases
in expression of this magnitude, with the notable exceptions of
clathrin, heavypolypeptide (CLTC, -1.2-fold) and synaptojanin
2 (SYNJ2,1.2-fold). These findings of increased expression of
NSF, synaptophysin, and other related genes are actually
opposite the findings reported in previous microarray studies
of postmortem brain tissue. Taken together, these observa-
tions reinforce the potential power of PBL expression data to
detect significant expression alterations of some of the same
genes implicated by postmortembrain tissue studies, although
the direction of change is not necessarily the same.
DISCUSSION
In this very preliminary study, we have explored the
potential utility of gene expression data acquired from PBLs
of subjects with schizophrenia or bipolar disorder and their
discordant age- and gender-matched siblings. Specifically, we
sought to: (1) identify those genes and functional gene groups
that are the most affected in the disease (pathophysioge-
nomics); (2) evaluate candidate genes and gene regions for
abnormal expression patterns that are correlated with known
locations of genetic linkage or association in the same popu-
lation; (3) identify genes with the greatest degree of diagnostic
utility; (4) search for candidate genomic loci that might be
involved in the primary disease pathogenesis; and (5) attempt
to correlate specific SNP haplotypes with altered expression
patterns. We briefly highlight some of our progress in each of
these aims.
Most Significantly Changed Genes in
Schizophrenia and Bipolar Disorder
It is not possible for us to reviewall of the single genefindings
in our dataset within the context of this preliminary report.
Thus, we have chosen to highlight a few of the observations
that we believe have particular novelty or relate to the pre-
existing literature on schizophrenia, bipolar disorder, or brain
function.
Schizophrenia. There were a number of genes among
those with the most significant increases in expression that
are known to be involved in immune and/or inflammatory
function (e.g., CD14 antigen, chemokine receptor 1; Table I).
Interestingly, however, we also detected a number of expres-
sion changes in genes that are known to be involved in
brain development (e.g., alpha catenin, neuregulin 1 (SMDF
variant)). The single most significantly affected gene was
TCFL4,whichwas 1.42-fold decreased,P¼ 0.0003), but did not
achieve a magnitude large enough to be listed in Table I. This
gene is also known as MAX-like protein (or MLX). We also
highlight the increase in expression of transducer of ERBB2,
2 (TOB2, 1.65-fold increased, P¼ 0.00014) (Table I). The
change in TOB2 is noteworthy because this gene is located in
close proximity to a schizophrenia susceptibility locus (22q13)
and because of the alteration in expression we observed for
neuregulin 1, SMDF (sensory andmotorneuronderived factor)
variant. TOB2 is a transducer of the tyrosine kinase receptors
from the ErbB family, which also exert control over NRG
signaling. The role of NRG is critical to early development of
the central nervous system and includes stimulation of
Schwann cell growth as well as generation of acetylcholine
receptors at the neuromuscular synapse [reviewed in Falls,
2003]. Of the seven splice variants of NRG on the array, only
TABLE VI. Top Loci Expression Alterations in Schizophenia and Bipolar Disorder
Bipolar disorder Schizophrenia
Chr MB
Z score
NPL >2
15 MB Chr MB
Z score
NPL >2
15 MBBP SCZ BP SCZ
6 52 13.72 0.08 2 72 1.48 11.48
21 31 11.84 1.05 15 37 2.31 11.38
20 23 10.78 0.03 Y 12 102 0.64 10.58
X 29 7.29 0.77 12 103 0.07 8.58
15 68 6.87 2.39 5 73 0.74 8.45
11 37 6.13 2.65 Y 1 7 1.19 8.08
18 45 5.59 0.62 6 130 1.45 7.32 Y
3 187 5.59 0.60 15 86 0.80 7.19
10 36 5.07 6.15 18 53 3.84 6.48
1 182 5.05 0.09 10 36 5.07 6.15
4 160 4.83 0.00 X 128 0.75 6.07
10 134 4.70 1.77 7 28 0.98 5.56
7 104 4.49 1.42 11 123 4.04 5.55
6 153 4.37 1.18 5 62 1.64 5.53
6 114 4.32 2.53 Y 5 126 0.25 5.34 Y
2 162 4.28 0.70 Y 5 44 0.74 5.33
8 74 4.24 1.46 3 24 2.31 5.30
19 39 4.20 0.17 Y 5 0 3.09 4.61
11 123 4.04 5.55 10 27 0.75 4.55 Y
3 174 3.98 0.15 13 28 0.00 4.46
18 53 3.84 6.48 5 68 1.73 4.13
11 129 3.77 1.35 4 186 2.02 4.03
6 152 3.68 2.82 X 14 0.51 3.85
8 67 3.56 0.38 Y X 71 0.22 3.82
1 86 3.53 0.95 4 157 2.64 3.69
Loci within 15 megabases (15 MB) of an NPL Z score >2.0 in this population are indicated for each disorder.
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the SMDF variant has altered gene expression in schizophre-
nic subjects versus controls. A full report on these findings was
recently reported elsewhere [Petryshen et al., 2004]. Together,
our data support further examination of the role of NRG
signaling in schizophrenia.
Bipolar disorder. Among the genes with the most con-
sistent and significant changes in expression was one not
previously reported in bipolar disorder, termedMAX (1.94-fold
increase, P¼ 0.015; Table II). The finding regarding increased
MAX expression in bipolar disorder is particularly interest-
ing in light of the increased expression of TCFL4/MLX in
schizophrenia. The MAX gene encodes for a member of the
basic region-helix-loop-helix-zipper proteins [Gilladoga et al.,
1992]. The MAX protein has been shown to associate with N-,
L-, and c-myc proteins [Gilladoga et al., 1992] and other
proteins and transcription factors, such as TCFL4. It has been
found that TCFL4 works in conjunction with ChREBP
(carbohydrate response element-binding protein) to regulate
the expression of genes responsive to glucose [Stoeckman et al.,
2004]. Interestingly, we also observed a number of transcripts
involved in G protein signaling to exhibit altered expression in
bipolar disorder (e.g., guanine nucleotide binding protein
(G protein), beta polypeptide 1; G protein-coupled receptor
kinase 5; Table II). Collectively, these data suggest there are
prominent changes in cellular transduction mechanisms in
this illness.
Functional Gene Group Alterations
Through the use of custom-written software, we were able
to analyze the expression patterns of entire groups of genes
that perform the same function in cells. The basis and utility of
TABLE VII. Location of TDT Peaks Relative to Expression Peaks in Bipolar Disorder
SNP Ids
Haplotype TDT
dof Chr Alleles MB
Expression
Chi square P-value Z (MB)
rs1392096 13.42 0.0198 5 1 C/T 205.3 3.31 (203)
rs1166868 C/T 205.5
rs4130547 A/G 205.8
rs1450344 10.43 0.0153 3 3 A/G 151.5 3.30 (153)
rs1388622 A/G 152.4
rs2210798 13.29 0.0013 2 6 C/T 8.5 1.93 (6)
rs1591454 C/G 8.5
rs2225765 A/G 8.5
rs2225766 A/G 8.5
rs2327577 13.33 0.0098 4 6 G/T 135.1 2.78 (135)
rs728030 G/T 135.2
rs2327578 C/T 135.3
rs724875 A/G 136.7
rs720565 C/G 136.7
rs721123 9.23 0.0264 3 7 G/T 146.3 2.80 (136)
rs721124 C/T 146.3
rs1406288 C/T 146.4
rs719311 A/T 147.0
rs719312 C/G 147.0
rs967306 11.33 0.0452 5 9 A/G 11.6 3.02 (2)
rs958842 G/T 11.7
rs1816823 C/T 11.7
rs2009463 C/G 11.7
rs956094 C/T 11.7
rs317155 11.33 0.0452 5 11 C/T 89.3 —
rs1986670 A/G 89.5
rs1986671 C/G 89.5
rs2167050 9.31 0.0023 1 11 A/C 132.1 3.77 (129)
rs921268 A/G 132.1
rs1512981 9.04 0.0287 3 12 A/G 71.1 —
rs1398562 G/T 71.2
rs2118087 9.83 0.0200 3 13 A/G 57.5 —
rs719193 G/T 57.6
rs2183493 A/G 58.0
rs2183492 9.83 0.0200 3 13 C/T 58.0 —
rs1330754 C/T 58.0
rs3901894 9.03 0.0289 3 13 C/G 95.2 —
rs544080 A/C 95.5
rs2899589 12.00 0.0025 2 15 A/G 53.4 1.62 (46)
rs725150 C/T 53.4
rs1382859 10.81 0.0045 2 15 C/G 90.4 2.16 (97)
rs1382860 A/G 90.4
rs717788 12.50 0.0285 5 17 C/T 11.7 —
rs1519252 A/G 12.5
rs1401539 G/T 12.5
rs952785 11.63 0.0088 3 18 C/T 57.3 3.84 (53)
rs582970 C/T 57.9
All expression peaks noted exceeded a Z score of 1.6 and were within 10 MB of the TDT peak.
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this approach has been reviewed previously [Middleton et al.,
2002, 2004]. In the present dataset, we have obtained
evidence that several major biological pathways related to
lipid and fatty acidmetabolismaredecreased inbipolar disorder
(e.g., sterol transporter, long-chain-fatty-acid–CoA ligase,
and cholesterol metabolism; Table VI). In the schizophrenia
dataset, these samegenegroupswerenot changed,althoughthe
group apolipoprotein A1/A4/E family was similarly decreased
(TableVI). Interestingly, among themost increasedgenegroups
in bipolar disorder was the group containing transcripts of the
Ezrin family. Ezrin interacts with actin to stabilize uptake
process (including the uptake of cholesterol), and has been
shown to be important in neurite outgrowth during cortical
formation. Ezrin itself is not apparently expressed in neurons,
but is abundant within radial glia and migrating cells in the
intermediate zone [Johnson et al., 2002]. Together, these data
suggest that subjects with schizophrenia and bipolar disorder
both exhibit alterations of molecules involved in fatty acid and
lipid metabolism that are vital to normal brain function,
although the specific genes showing the greatest changes are
distinct for each disorder.
Classification by Gene Expression
We tested the ability of our dataset to correctly distinguish
subjects with schizophrenia or bipolar disorder from their
unaffected discordant sibs using the nearest neighbor class
predictor algorithm (GeneSpring). An iterative approach was
used to determine the number of genes and gene neighbors
that produced the highest accuracy. The use of 35 potential
candidates and 7nearest neighbors successfully classified 70 of
76 subjects in accordance with their true diagnosis (i.e.
unaffected, BP or SCZ).
Of the six misclassified or unclassified subjects, three SCZ
patients were classified as BP, one SCZ was misclassified as
unaffected, and two subjects were not classified. Thus, in its
initial training set, the algorithm had an accuracy of classifi-
cation of 87% for schizophrenia (27 of 31 correct diagnoses) and
89% for the combined SCZ and BP subject sets (32 of 36 correct
diagnoses). We wish to stress that the small number of BP
subjects used in this study likely contributed to a less distinct
predictor gene set being obtained for this disease. Interest-
ingly, only one patient was misclassified as an unaffected
subject. Moreover, two of the subjects with schizophrenia that
were classified as probable bipolar subjects actually had family
histories of bipolar disorder and/or carried a Best Estimate
Diagnosis of schizoaffective disorder. By convention, schizoaf-
fective disorder, depressed has been considered affected in
schizophrenia linkage studies and schizoaffective disorder,
bipolar has been considered affected in bipolar linkage studies.
This convention may promote confounds that would limit
the ability of gene expression profiling. For example, if we
eliminate those schizoaffective subjects that were classified as
schizophrenics in our linkage studies, three of the four
classification errors would be removed. This would increase
the diagnostic accuracy to 96% (27 of 28 correct). Although
preliminary, this observation highlights the need for careful
evaluation of the nature of schizoaffective disorder and the use
of these patients as part of the core phenotype definition. In
addition to the nearest neighbor method, we also obtained
100% accurate classification using a SVMmodel with our gene
expression data. Most of the genes with the highest predictive
strengthwere the same for these twomethods, and are listed in
Table IV. Notably, several of these predictor genes are located
on the loci of interest (e.g., alpha catenin) or have been
previously mentioned (e.g., TCFL4).
Cytogenomic Mapping of Expression
Data Compared to Linkage/LD Data
Our method of analyzing the expression of groups of genes
in close physical proximity (cytogenomics) has provided clear
examples where the abnormalities converge with the loci
identified through linkage and/or association screening.
Despite the clear limitations of this preliminary study, our
results support the potential utility of this multifaceted
approach to the study of neuropsychiatric illness. Based on
this approach, however, we have already extended these
results to specifically test candidate genes within the 5q
linkage region in schizophrenia that displayed abnormal
expression patterns and found significant relationships to
haplotype-linkagedisequilibriuminthe sameregion [Petryshen
et al., 2004].
CONCLUSIONS
Overall, we find that screening of gene expression patterns
in PBLs of subjects with schizophrenia or bipolar disorder
shows potential both in terms of diagnostic utility as well as
revealing new biological insights into these disorders. Much of
the data we are accumulating point toward alterations
of specific loci and specific biological pathways in each illness.
We recognize the need for follow-up studies of our results.
Nonetheless, the data we present provide a framework for our
ongoing research and allow other groups to test specific
hypotheses in their datasets.
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TABLE VIII. Representative Real-Time Quantitative RT-PCR Validation Assays
Disease Gene Location
Array Finding (n¼33 pairs) Real-time (n¼ 19 pairs)
Fold Chg P-value # Probes Fold Chg P-value # Repl
BP RNA polymerase II, A 17p13.1 1.09 0.497 1 1.02 0.485 2
SCZ Alpha tubulin, ubiquitous 12q13.12 1.04 0.640 5 1.02 0.170 4
SCZ ADAM 19 5q33.3 1.11 0.180 2 1.28 0.026 3
SCZ Serotonin receptor 4 5q33.1 1.14 0.053 3 1.31 0.018 3
SCZ Synaptobrevin 2 (VAMP2) 17p13.1 1.08 0.030 1 1.23 0.074 3
SCZ TCFL4 17q21 1.27 0.010 3 1.18 0.048 2
SCZ Neuregulin 1, SMDF variant 8p21-p12 1.72 0.012 1 3.80 0.014 3
Correlation in reported differences (log2 scale) for seven transcripts. Array versus PCR: R¼ 0.951.
P-value superscripts indicate # tails.
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